Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel psoriasis susceptibility locus

被引：0
|
作者：
Merleev, A. [1 ]
Toussi, A. [1 ]
Downing, L. [1 ]
Tran, M. [1 ]
Nava, J. [1 ]
Le, S. [1 ]
Marusina, A. [1 ]
机构：
[1] Univ Calif Davis, Dermatol, Sacramento, CA 95817 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2021年 / 141卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
005
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [2] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [3] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
  • [4] Regulation of ENaC by proprotein convertase subtilisin/kexin type 9(PCSK9)
    Sharotri, Vikas
    Snyder, Peter M.
    FASEB JOURNAL, 2010, 24
  • [5] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP"
    Silverstein, Roy L.
    CIRCULATION, 2021, 143 (01) : 62 - 64
  • [6] Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
    Imaralu, Omonzejie E.
    Narasimhulu, Chandrakala Aluganti
    Singal, Pawan K.
    Singla, Dinender K.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (01) : 14 - 25
  • [7] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Rainer Schulz
    Klaus-Dieter Schlüter
    Ulrich Laufs
    Basic Research in Cardiology, 2015, 110
  • [8] Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Schulz, Rainer
    Schlueter, Klaus-Dieter
    Laufs, Ulrich
    BASIC RESEARCH IN CARDIOLOGY, 2015, 110 (02)
  • [9] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [10] Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
    Bell, Andrew S.
    Wagner, Josephin
    Rosoff, Daniel B.
    Lohoff, Falk W.
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2023, 149
12345